New England Journal of Medicine May 26, 2016

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease (HOPE-3)

Salim Yusuf, Eva Lonn, Prem Pais, Jackie Bosch, Patricio López-Jaramillo, Jun Zhu, et al. (HOPE-3 Investigators)

Bottom Line

In an intermediate-risk primary prevention population, the fixed-dose combination of rosuvastatin and candesartan/hydrochlorothiazide significantly reduced cardiovascular events compared to dual placebo, an effect driven almost entirely by the statin component.

Key Findings

1. Combined Therapy vs. Dual Placebo: The first coprimary outcome (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 3.6% (113 of 3,180) of the combined-therapy group versus 5.0% (157 of 3,168) of the dual-placebo group (HR 0.71; 95% CI, 0.56-0.90; P=0.005).
2. The second coprimary outcome (first coprimary outcome plus heart failure, resuscitated cardiac arrest, or revascularization) occurred in 4.3% of the combined-therapy group compared to 5.9% of the dual-placebo group (HR 0.72; 95% CI, 0.57-0.89; P=0.003).
3. Compared with dual placebo, combined therapy resulted in a 33.7 mg/dL (0.87 mmol/L) greater reduction in LDL cholesterol and a 6.2/3.2 mm Hg greater reduction in blood pressure over the trial duration.
4. The overall cardiovascular benefit of the combined therapy was driven primarily by the rosuvastatin component (which independently reduced the primary endpoint by 24%, HR 0.76). Candesartan/hydrochlorothiazide alone did not significantly reduce cardiovascular events compared to placebo overall, but did show benefit in a prespecified subgroup with baseline systolic blood pressure >143.5 mm Hg.

Study Design

Design
RCT (2x2 Factorial)
Double-Blind
Sample
12,705
Patients
Duration
5.6 yr
Median
Setting
Multicenter, 21 countries
Population Intermediate-risk individuals (men ≥55 years, women ≥65 years with ≥1 cardiovascular risk factor) without established cardiovascular disease.
Intervention Combined therapy: Rosuvastatin 10 mg + candesartan 16 mg / hydrochlorothiazide 12.5 mg daily
Comparator Dual matching placebos
Outcome Coprimary: 1) Composite of CV death, nonfatal MI, or nonfatal stroke; 2) Coprimary 1 plus heart failure, resuscitated cardiac arrest, or revascularization.

Study Limitations

The enrolled population had a relatively low baseline blood pressure (mean 138/82 mm Hg), which likely attenuated the potential to observe a significant cardiovascular benefit from the antihypertensive arm across the entire cohort.
The event rate in this intermediate-risk population was lower than initially anticipated, resulting in modest absolute risk reductions over the 5.6-year follow-up period.
Approximately 25% of participants discontinued their assigned trial regimen by the end of the study (often due to non-study drug initiation or patient preference), which may have diluted the observed treatment effect.
The fixed-dose 'polypill' approach without titration targets departs from individualized, precision medicine algorithms, limiting conclusions about whether a target-driven strategy would have yielded different results.

Clinical Significance

HOPE-3 strongly cemented the role of moderate-intensity statin therapy (rosuvastatin 10 mg) for primary prevention in globally diverse, intermediate-risk individuals, regardless of baseline LDL cholesterol levels. Conversely, it demonstrated that routine, empiric blood pressure lowering with candesartan/hydrochlorothiazide provides no cardiovascular event reduction in intermediate-risk individuals without overt hypertension. This supports broad population-level statin use for intermediate risk while recommending a threshold-based approach (e.g., initiating therapy when systolic BP >143.5 mm Hg) for antihypertensives.

Historical Context

The HOPE-3 trial was conceived to test the 'polypill' concept originally proposed by Wald and Law in 2003, which hypothesized that combining low-cost, fixed-dose generic blood pressure and cholesterol-lowering medications could drastically reduce global cardiovascular disease burden without complex screening or titration. While earlier trials like ASCOT-LLA and JUPITER demonstrated primary prevention benefits with statins in specific hypertensive or high-hsCRP populations, HOPE-3 broadened this evaluation to a diverse, global, intermediate-risk population without mandating strict baseline lipid or blood pressure thresholds.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

The HOPE-3 trial used a fixed dose of rosuvastatin rather than titrating to a specific LDL target. Based on the mechanism of statins and cardiovascular risk pathophysiology, why might a fixed-dose approach be biologically effective in an intermediate-risk population regardless of their baseline LDL?

Key Response

Statins competitively inhibit HMG-CoA reductase, leading to upregulation of hepatic LDL receptors and clearance of circulating LDL. The trial emphasizes that baseline LDL does not strictly dictate the relative risk reduction of statins; the pleiotropic effects (such as plaque stabilization and improved endothelial function) and the absolute proportional LDL lowering provide consistent cardiovascular benefit in intermediate-risk individuals, validating a simpler primary prevention strategy.

Resident
Resident

How does the finding that candesartan/HCTZ only reduced cardiovascular events in the upper tertile of baseline blood pressure (systolic >143.5 mm Hg) influence your clinical threshold for initiating antihypertensive therapy in intermediate-risk patients?

Key Response

This finding supports the clinical principle that, unlike statins, blood pressure-lowering medications should be initiated based on baseline physiological measurements rather than global cardiovascular risk alone in primary prevention. It reinforces the resident's decision to avoid prescribing empiric BP-lowering agents to normotensive patients simply because they possess other cardiovascular risk factors.

Fellow
Fellow

The HOPE-3 trial utilized a 2x2 factorial design to assess both lipid and blood pressure lowering. What are the clinical and statistical implications of this design for evaluating the 'polypill' concept, and how did the trial address the potential interaction between the two distinct interventions?

Key Response

A 2x2 factorial design efficiently answers two independent questions (statin efficacy and BP efficacy) within the same cohort, maximizing statistical power. Clinically, it evaluates the combined 'polypill' approach. Fellows must recognize that the trial tested for statistical interaction between the two arms and found none, meaning the relative benefits of the statin were consistent regardless of whether the patient received active antihypertensive therapy.

Attending
Attending

Given the HOPE-3 findings that an empiric 10 mg dose of rosuvastatin significantly reduced events without routine lipid monitoring, how might you restructure primary care workflows to maximize population-level cardiovascular disease prevention while minimizing healthcare burden?

Key Response

This trial supports a paradigm shift from a 'treat-to-target' approach requiring frequent lab draws to a 'fire-and-forget' fixed-dose strategy. Attendings can use this evidence to advocate for reducing systemic barriers to adherence (e.g., less bloodwork, simpler regimens) to achieve broad population health benefits, recognizing that the vast majority of risk reduction is achieved simply by initiating the statin.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

The HOPE-3 trial defined intermediate cardiovascular risk primarily by age and simple clinical criteria rather than utilizing comprehensive equations like the Pooled Cohort Equations. How does this pragmatic inclusion criterion impact the epidemiological interpretation of its absolute risk reduction and the trial's generalizability?

Key Response

By omitting calculated risk scores requiring specific lab values, the trial's population is highly pragmatic and globally representative, particularly for low-resource settings. However, the annualized event rate in the placebo group was lower than expected (roughly 1%), which dilutes the absolute risk reduction (ARR) and increases the number needed to treat (NNT). Methodologists must consider whether this inclusion strategy makes the intervention appear less cost-effective compared to targeting populations defined by precise risk calculators.

Journal Editor
Journal Editor

As an editor evaluating the HOPE-3 manuscript, how would you scrutinize the trial's overall statistical power considering the actual event rate was lower than the authors initially projected, and what threats to validity does this introduce for the blood pressure arm's null findings?

Key Response

A seasoned editor would flag that lower-than-expected event rates compromise statistical power, raising the possibility of a Type II error in the blood pressure arm. The critique would focus on whether the lack of overall benefit from BP lowering was a true biological lack of effect in this demographic or simply a failure to detect a smaller, but clinically meaningful, difference due to an underpowered sample size in a relatively healthy cohort.

Guideline Committee
Guideline Committee

How do the HOPE-3 results regarding blood pressure lowering in intermediate-risk populations align with or challenge the ACC/AHA 2017 hypertension guidelines, specifically the recommendation to initiate pharmacological treatment at a BP of >130/80 mm Hg for patients with an ASCVD risk >10%?

Key Response

The ACC/AHA 2017 guidelines advocate treating to <130/80 mm Hg for those with elevated global ASCVD risk. However, HOPE-3 demonstrated no cardiovascular benefit from lowering BP in intermediate-risk patients whose baseline systolic BP was in the lower two tertiles (<143.5 mm Hg). Guideline committees must weigh this high-quality RCT evidence, which suggests a higher baseline BP threshold is necessary for benefit in primary prevention, against the epidemiological risk models and SPRINT data that drove the ACC/AHA target shift.

Clinical Landscape

Noteworthy Related Trials

2003

ASCOT-LLA Trial

n = 10,305 · Lancet

Tested

Atorvastatin 10 mg daily

Population

Hypertensive patients with at least three other cardiovascular risk factors but no prior coronary heart disease

Comparator

Placebo

Endpoint

Non-fatal myocardial infarction and fatal coronary heart disease

Key result: Atorvastatin significantly reduced the incidence of non-fatal MI and fatal CHD by 36 percent compared to placebo.
2008

JUPITER Trial

n = 17,802 · NEJM

Tested

Rosuvastatin 20 mg daily

Population

Healthy individuals with LDL less than 130 mg/dL and hsCRP 2.0 mg/L or greater

Comparator

Placebo

Endpoint

First major cardiovascular event (MI, stroke, arterial revascularization, hospitalization for unstable angina, or CV death)

Key result: Rosuvastatin significantly reduced the incidence of major cardiovascular events by 44 percent.
2015

SPRINT Trial

n = 9,361 · NEJM

Tested

Intensive blood-pressure control (target systolic less than 120 mm Hg)

Population

Adults at high risk for cardiovascular events but without diabetes or prior stroke

Comparator

Standard blood-pressure control (target systolic less than 140 mm Hg)

Endpoint

Composite of myocardial infarction, other acute coronary syndromes, stroke, heart failure, or cardiovascular death

Key result: Intensive blood-pressure control significantly lowered the rate of the primary composite outcome and all-cause mortality.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis